Generic Drugs

Gilead Reaches Settlement To Block Biktarvy Generics Until 2036
Gilead Reaches Settlement To Block Biktarvy Generics Until 2036
Kodak CEO Says Moving Forward On Generic Drug Ingredients Venture, With or Without Federal Loan
Kodak CEO Says Moving Forward On Generic Drug Ingredients Venture, With or Without Federal Loan
US Indicts Teva Pharmaceutical In Generic Drug Price-Fixing Case
US Indicts Teva Pharmaceutical In Generic Drug Price-Fixing Case
Kodak CEO Says Moving Forward On Generic Drug Ingredients Venture, With or Without Federal Loan
Kodak CEO Says Moving Forward On Generic Drug Ingredients Venture, With or Without Federal Loan
US Indicts Teva Pharmaceutical In Generic Drug Price-Fixing Case
US Indicts Teva Pharmaceutical In Generic Drug Price-Fixing Case
Teva CEO Kare Schultz On Drugmaker's Outlook, Coronavirus Response
Teva CEO Kare Schultz On Drugmaker's Outlook, Coronavirus Response
Teva Plummets Amid Massive Price Fixing Scheme; Other Generic Drugmakers Also Fall
Teva Plummets Amid Massive Price Fixing Scheme; Other Generic Drugmakers Also Fall

Generic Drugs Recent News

Goldman Sachs On Specialty Pharma: Buy Catalent, Sell Valeant
Goldman Sachs On Specialty Pharma: Buy Catalent, Sell Valeant
Teva's Cost-Cutting Plan Nets A Mizuho Upgrade
Teva's Cost-Cutting Plan Nets A Mizuho Upgrade
Mallinckrodt Sees Slight Positive From Tax Reform, Up To $500 Million Benefit
Mallinckrodt Sees Slight Positive From Tax Reform, Up To $500 Million Benefit
Analyst: Despite Industry Woes, Investigations, And Management Shake-Up, Perrigo Is A Buy
Analyst: Despite Industry Woes, Investigations, And Management Shake-Up, Perrigo Is A Buy
For Teva Pharmaceuticals, No Recovery In Sight, Says Analyst
For Teva Pharmaceuticals, No Recovery In Sight, Says Analyst
RBC: Perrigo's Near-Term Risk Lessens, But Long-Term Issues Persist
RBC: Perrigo's Near-Term Risk Lessens, But Long-Term Issues Persist
Adamas Pharma's Gocovri Will Achieve 'Blockbuster' Status, Says Kerrisdale
Adamas Pharma's Gocovri Will Achieve 'Blockbuster' Status, Says Kerrisdale
Endo International Piques Investor Interest After Raising Guidance
Endo International Piques Investor Interest After Raising Guidance
Why Is Teva Falling? Competition
Why Is Teva Falling? Competition
A Look At Teva's Paragard IUD Asset Sale To Cooper Companies, From Both Sides
A Look At Teva's Paragard IUD Asset Sale To Cooper Companies, From Both Sides
Teva's New CEO Is A Positive Catalyst
Teva's New CEO Is A Positive Catalyst
Mylan's Stock Is No Longer A Buy According To Analysts At Argus
Mylan's Stock Is No Longer A Buy According To Analysts At Argus
Teva's Quarter: Earnings Miss, Guidance Cut, Dividend Devastated
Teva's Quarter: Earnings Miss, Guidance Cut, Dividend Devastated
Teva's Stock Inches Higher Amid Cost-Cutting Plan
Teva's Stock Inches Higher Amid Cost-Cutting Plan
Citron On Lannett: Price Gouging At Its Worst, Will Be First To Go Bankrupt
Citron On Lannett: Price Gouging At Its Worst, Will Be First To Go Bankrupt
Report: Teva Looking To Win Early EU Approval For Its Acquisition Of Allergan's Generics Unit
Report: Teva Looking To Win Early EU Approval For Its Acquisition Of Allergan's Generics Unit
AstraZeneca Falls More Than 5% Following Q4 Print
AstraZeneca Falls More Than 5% Following Q4 Print
Express Scripts Calls Out Valeant, Says It's 'Holding Pharmaceutical Manufacturers Accountable For Excessive Price Hikes'
Express Scripts Calls Out Valeant, Says It's 'Holding Pharmaceutical Manufacturers Accountable For Excessive Price Hikes'
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2025 Benzinga | All Rights Reserved